Practitioner's Docket No. MPI97-018CP1DV1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Moore, Karen J., et al

November 28, 2000

Application No.:

09/724,392

Group No.:

1646

1040

Examiner:

J.F. Murphy

Filed:

NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR

Commissioner for Patents Washington, DC 20231

Dear Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated September 13, 2002 (Paper No. 7), Applicants hereby elect Group V, drawn to methods for identifying a compound capable of modulating I5E activity (claims 32-46), without prejudice to Applicant's right to pursue the additional subject matter in other applications. Applicants hereby reserve the right to traverse the above restriction with respect to non-elected Groups I-IV, and VI-XII in this or subsequent applications.

It is believed this paper is being filed timely, and no extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

10 Oct	ober 2002	MILLENNIUM PHARMACEUTICALS, INC.
10 00	300, 2002	By Kerri Pollard Schray
		Registration No. 47,066
		75 Sidney Street
		Cambridge, MA 02139
		Telephone - 617-551-3676
		Facsimile - 617-551-8820
CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*		
hereby certify that, on the date shown below, this correspondence is being: MAILING		
-		in an envelope addressed to the Assistant Commissioner for Patents,
X	Washington, D.C. 20231.	
	37 C.F.R. SECTION 1.8(a)	37 C.F.R. SECTION 1.10*
	with sufficient postage as first class mail.	as "Express Mail Post Office to Address" Mailing Label No.
TRANSMISSION		
XI	transmitted by facsimile to the Patent and Trad-	lemark Office. Signature
		V

Date: 10 October 2002

Kerri Pollard Schray

(type or print name of person certifying)

(Page 1 of 1)